Episodes
Friday Aug 11, 2023
Making the GRADE: Durability of Glycemic Response in Type 2 Diabetes
Friday Aug 11, 2023
Friday Aug 11, 2023
Type 2 diabetes (type 2 DM) is a progressive disease caused by a variety of pathophysiologic defects. However, even with substantial advances in treatment, glycemic control remains elusive, and most patients require combination therapy. The Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness (GRADE) study sought to investigate the glucose-lowering efficacy of several diabetes medications in combination with metformin.
Guest Authors: Katelyn Currier, PharmD and Jennifer Trujillo, PharmD, BCPS, CDCES, BC-ADM
Music by Good Talk
Friday May 12, 2023
GLP-1 Receptor Agonists and SGLT2 Inhibitors: Don’t Sugarcoat the Costs!
Friday May 12, 2023
Friday May 12, 2023
The cost of diabetes in the United States has nearly doubled over the past decade in part due to rising prices and the cost of newer medications used to manage the disease. With new, improved, but costly alternatives available, it’s going to be challenging for ambulatory care practitioners to evaluate if the potential benefits of using these newer medication classes as first-line therapy (instead of metformin) outweigh their big price tag.
Guest Authors: Amanda Smith, PharmD and Nicole Slater, PharmD, BCACP
Music by Good Talk
Friday Apr 28, 2023
Friday Apr 28, 2023
Several medication classes can be used to treat diabetic peripheral neuropathic pain (DPNP); however, many patients have a suboptimal response or experience dose-limiting side effects. Treatment guidelines suggest several first-line options but, in the absence of compelling evidence, offer no direction as to which agent to try first or if we should consider combination therapy.
Guest Authors: Shilpa Klocke, PharmD, BCPS and Nicole Hahn, PharmD, BCACP
Music by Good Talk
Saturday Feb 18, 2023
Top Ten Things Every Clinician Should Know About Treating Obesity
Saturday Feb 18, 2023
Saturday Feb 18, 2023
Obesity is a chronic, progressive, multi-factorial, neurobehavioral disease characterized by excessive adipose tissue. Here are some things every clinician should know about treating overweight and obesity but be sure to read the written commentary posted on iForumRx.org
Guest Authors: Jennifer N. Clements, PharmD, BCPS, BCACP, CDCES, BC-ADM and Seena L. Haines, PharmD., BCACP, NBC-HWC, CHWC
Music by Good Talk
Tuesday Aug 02, 2022
Tuesday Aug 02, 2022
This episode is a collaboration between the ACCP Ambulatory Care Practice and Research Network (PRN) ... and iForumRx.org.
Wondering if a continuous glucose monitor (CGM) is right for your patient? Worried about workflow, prior authorization, billing, and payment? Our expert panelists explain how they manage patients in their practices and how they bill for their services.
Guests: Jennifer Trujillo, PharmD, BCPS, CDCES, BC-ADM; Edward Saito, PharmD, BCACP; and Christina Sherrill, PharmD, BCACP, CPP
Produced by Jonathan Hughes, PharmD, BCPS, BCACP and Anna Love, PharmD, BCACP
Music by lemonmusicstudio from Pixabay
Tuesday Jul 26, 2022
A Healthier Way to Commute? Cycling Reduces Mortality in Patients with Diabetes
Tuesday Jul 26, 2022
Tuesday Jul 26, 2022
Physical activity is critical to preventing and treating diabetes and reduces cardiovascular disease (CVD) and mortality. Although moderate-to-high intensity aerobic exercise of any type is likely beneficial, cycling is particularly attractive because it is a low-impact exercise (e.g. easier on the joints) and can potentially be used as a transportation method.
Guest Author: Kristin Lutek, PharmD, BCACP, CDCES
Special Guest: Seena L. Haines, PharmD, BCACP, NBC-HWC
Music by Good Talk
Thursday Apr 21, 2022
Thursday Apr 21, 2022
Published in Diabetes Care every January, the Standards of Medical Care in Diabetes by the American Diabetes Association (ADA) provides recommendations for the care of patients with diabetes. And every year clinicians eagerly read, discuss, and apply them in their practices. In this episode, we discuss some of the highlights.
Guest Author: Jennifer N. Clements, PharmD, BCPS, BCACP, CDCES, BC-ADM
Special Guest: Joshua Neumiller, PharmD, CDCES
Music by Good Talk
Friday Dec 31, 2021
Friday Dec 31, 2021
Continuous glucose monitors (CGMs) are now commonplace, and every clinician should know the basics about who can benefit from CGM use and how to address common questions and problems.
Authors: Brianna Patacini, PharmD, BCACP, CDCES and Dawn Fuke, PharmD, BCPS
Special Guest: Jennifer Trujillo, PharmD, BCPS, CDCES, BC-ADM
Music by Good Talk
Friday Dec 03, 2021
Will a Dual GIP/GLP-1 Receptor Agonist SURPASS the Crowd?
Friday Dec 03, 2021
Friday Dec 03, 2021
There are now over 30 unique therapeutic entities (and countless different products!) to treat hyperglycemia in patients with type 2 diabetes mellitus (T2DM). While the glucagon-like peptide-1 (GLP-1) receptor agonists improve glycemic control, renal, and cardiovascular outcomes and induce significant weight loss, drugs that target more than one incretin hormone may have even greater therapeutic benefits.
Guest Authors: Nadila Faridi, PharmD and Kathleen Pincus, PharmD, BCPS, BCACP
Special Guest: Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES
Music by Good Talk
Thursday Jun 24, 2021
Raised From The Grave: A Second Life for Sotagliflozin?
Thursday Jun 24, 2021
Thursday Jun 24, 2021
The prevalence of heart failure in patients with diabetes is four times higher than in the general population. Likewise, chronic kidney disease (CKD) and diabetes are common morbidities. As new drug classes emerge in the management of diabetes and heart failure and CKD, it is important to thoroughly evaluate available literature and identify opportunities to reduce complications and costs. Sotagliflozin is a first-in-class dual SGLT-1 and 2 inhibitor approved in Europe. Does it improve outcomes in patients with heart failure or CKD?
Guest Authors: Maren Richards Brinton, PharmD and Jonathan C. Hughes, PharmD, BCPS, BCACP
Music by Good Talk